Prostate Cell News Volume 7.25 | Jul 15 2016

TOP STORY

Prostate Cancer: Unexpected Results from International Phase III Study

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [Press release from Medical University of Vienna discussing online prepublication in Journal of Clinical Oncology] Press Release | Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Snail Promotes Resistance to Enzalutamide Through Regulation of Androgen Receptor Activity in Prostate Cancer

Scientists elucidated the functional consequence of induced epithelial plasticity on androgen receptor regulation during disease progression to identify factors important for treatment-resistant and metastatic prostate cancer. [Oncotarget] Full Article

Co-Targeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer

Researchers found that co-treatment of prostate cancer with androgen receptor (AR) antagonist enzalutamide and HSP90 inhibitor leads to more severe cell death due to a synergistic reduction of AR protein. [Mol Cancer Ther] Abstract

Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease HSP90 and the Androgen Receptor Levels and Inhibit Viability in Enzalutamide Resistant C4-2 Prostate Cancer Cells

Scientists designed hybrid molecules containing partial chemical scaffolds of enzalutamide and suberoylanilide hydroxamic acid, with weakened intrinsic pan-histone deacetylase inhibitor activities, to target heat shock protein (HSP) 90 and androgen receptor in enzalutamide-resistant prostate cancer cells [Mol Pharmacol] Abstract | Full Article

Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain in Prostate Cancer Cells

Investigators explored the biological effects of metformin on prostate cancer cells and determined molecular pathways and epigenetic regulators implicated in its mechanism of action. [Prostate] Abstract

Neuronal Trans-Differentiation in Prostate Cancer Cells

Investigators found that LNCaP cells, subjected to a variety of stressors induced a reproducible phenotype consistent with neuronal trans-differentiation. Cells developed long cytoplasmic processes resembling neurons. [Prostate] Abstract

Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells

Researchers found that lambertianic acid exerts the anticancer effect by inhibiting AR and is a valuable therapeutic agent in prostate cancer treatment. [Int J Mol Sci] Full Article

Development of a 3D Tissue Culture–Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases

Scientists described a high-content screening platform that used invasive human prostate cancer cells cultured in 3D in standard 384-well assay plates to study the activity of potential therapeutic small molecules and antibody biologics. [J Biomol Screen] Abstract

CLINICAL RESEARCH

Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer

Researchers reported unexpected antitumor activity seen in metastatic castration resistant prostate cancer patients treated with the anti-programmed cell death-1 (PD-1) antibody pembrolizumab. [Oncotarget] Full Article | Press Release

TRPM8 Puts the Chill on Prostate Cancer

The authors reviewed inventory advances in understanding of the role of transient receptor potential melastatin member 8 (TRPM8) in the installation and progression of prostate cancer. [Pharmaceuticals] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Statins May Be Associated with Reduced Mortality in Four Common Cancers

A diagnosis of high cholesterol is associated with reduced mortality and improved survival in the four most common cancers. The 14 year study from nearly one million patients found that a high cholesterol diagnosis was associated with lower risk of death in lung, breast, prostate and bowel cancers. [Press release from the European Society of Cardiology discussing research presented at Frontiers in CardioVascular Biology, Florence] Press Release

Laborie Completes Stractegic Investment in Medi-Tate LTD.

Laborie Medical Technologies (Laborie), has completed an investment in Medi-Tate Ltd. Medi-Tate has developed iTind, a minimally invasive procedure to treat the symptoms of enlarged prostate in men whose primary other treatment options would be pharmaceutical therapy or surgery. [Laborie Medical Technologies] Press Release

Sun Pharma Launches Gemcitabine InfuSMART, World’s First Licensed Ready-To-Administer Bag for Oncology Treatment

Sun Pharma announced the roll-out of Gemcitabine InfuSMART in Europe. InfuSMART is a technology in which oncology products are developed in a Ready-To-Administer bag. [Sun Pharmaceutical Industries Ltd.] Press Release (Download)

Science’s Status Shifts in New Brexit Government

Three weeks after UK voters chose to leave the European Union, the country has a new prime minister, Theresa May — and a revamped administration that is poised to change science’s place in government. [Nature News] Editorial

Policy: Five Cornerstones of a Global Bioeconomy

Bioscience leaders such as the European Union, Japan and the United States see expanding the bioeconomy as a means of reindustrializing and creating wealth. Emerging industrial economies such as China and India see biotechnology as a nascent field of innovation in which they can quickly compete. Brazil, South Africa and Malaysia are investing to add value to their vast biological resources. [Nature News] Editorial

NEW Nordic Life Science Days 2016
September 14-15, 2016
Stockholm, Sweden

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Fellow – Breast, Prostate and Pancreatic Cancer (MD Anderson Cancer Center)

NEW Postdoctoral Fellow – Epigenetics and Cell Differentiation (Centre National de la Recherche Scientifique)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Clinical Laboratory Scientist (GenomeDx)

Associate Editor (PLOS ONE)

Faculty Positions – Cancer Immunology (University of New Mexico Health Science Center)

Postdoctoral Position – Molecular Biology/Prostate Cancer (FIBICO)

Postdoctoral Associate – Cancer Research (Sanford Burnham Prebys Medical Discovery Institute)

Postdoctoral Scientist – Cancer Biology (Medical Research Council)

Postdoctoral Fellow – Cancer Research (University of California – San Francisco)

Postdoctoral Fellow – Signaling and Epigenetic Regulation (Medical University of South Carolina)

Postdoctoral Fellow – Prostate Cancer and Metabolism (Cleveland Clinic)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.